Taken together, these data underscore the importance of generating immune-humanized models for ER+ breast cancer to better define tumor-host interactions and improve patient outcome by uncovering strategies to make this disease more responsive to immunotherapy. The gene discussed is ESR1; the disease is breast carcinoma.